Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

ncer cells. It is unique because, in contrast to competing agents, TB-403 only blocks blood vessels in tumour tissue and not in healthy tissue. This novel product, which acts on PIGF, is being co-developed with BioInvent International.

TB-403 is attracting growing interest from potential pharma partners based on both the need for improved products for the treatment of cancer and the exciting pre-clinical results which were published in a Cell feature article in the November 2, 2007 issue.(1)

The commercial potential of TB-403 could also be enhanced as TB-403 could also be used to treat a number of important back of the eye diseases. This is because common eye diseases such as age-related macular degeneration and diabetic retinopathy are caused by uncontrolled blood vessel growth, which could be halted using TB-403.

The Remainder of 2008

ThromboGenics expects to deliver a number of value creating clinical milestones during the remainder of 2008. The expected milestones over this period are:

Microplasmin

- Top line results are expected from the MIVI III Phase IIb trial of microplasmin in vitrectomy in June 2008.

ThromboGenics began the MIVI III Phase IIb trial in January 2007. The trial is evaluating the safety and efficacy of microplasmin intravitreal injection seven days prior to vitrectomy. The results from this trial will be presented at the World Ophthalmology Congress in Hong Kong on June 28, 2008.

Based on the results of this trial, ThromboGenics will select the best dose of microplasmin for use in two separate Phase III studies, one US and one European based. These trials, which are designed to clearly demonstrate the efficacy of microplasmin, are expected to begin before the end of 2008.

- Six month results from the MIVI IIT Phase IIa trial of microplasmin in vitreomacular traction are to be presented at the Euretina Conference in May.

The six month results from the first two cohorts of thi
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 BioNano Genomics, Inc., the leader ... institutes, announced today that a collaboration led by the ... the creation of the first comprehensive analysis of a ... methods for sequencing and genome mapping. This study, published ... analysis of the contiguous diploid human genome assembly obtained ...
(Date:6/29/2015)... Md. , June 29, 2015  Neuralstem, Inc. ... cell technology to develop small molecule and cell therapy ... it has been approved for listing on the NASDAQ ... stock will continue to trade on the NYSE MKT ... on the NASDAQ Capital Market is expected to commence ...
(Date:6/29/2015)... 2015   Veracyte, Inc . (Nasdaq: VCYT ... molecular cytology, today announced that it has been named ... list for the second year in a row. The ... an annual survey of Bay Area-company employees. ... to which Veracyte values our employees and their individual ...
(Date:6/26/2015)... Mass. , June 26, 2015  SeraCare ... vitro diagnostics manufacturers, today announced that it has ... with the National Cancer Institute (NCI), part of ... materials and positive controls for cancer assays.  The ... mix and accurately quantitate control DNA biosynthetics spiked ...
Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Beck and C. Schmidt, Varian, Inc. , ... Marijuana is one of the most commonly used illegal recreational drugs in ... is tetrahydrocannabinol or THC. Toxicology, forensic, and clinical labs are often asked ... of THC, most frequently the carboxy form. , ...
... BD Biosciences is pleased to introduce the BD ... (Cat. No. 558142) for the isolation of Treg cells ... isolates Treg cells in two stages. First, negative selection ... cocktail of biotinylated monoclonal antibodies that recognizes antigens expressed ...
... , Introduction ... the cell cycle is commonly used in cell biology since many pharmacological ... here an application that can be used in adherent cells and optionally ... , The cell cycle consists of ...
Cached Biology Technology:Analysis of ()-11-Nor-9-Carboxy-Delta-9-THC in Urine by Negative Ion Electrospray LC/MS/MS 2Analysis of ()-11-Nor-9-Carboxy-Delta-9-THC in Urine by Negative Ion Electrospray LC/MS/MS 3Quantitative Analysis of the Cell Cycle in Imaging Applications 2Quantitative Analysis of the Cell Cycle in Imaging Applications 3Quantitative Analysis of the Cell Cycle in Imaging Applications 4Quantitative Analysis of the Cell Cycle in Imaging Applications 5
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... Nature, the authors including Dr Ying ... Climate Research say that nitrogen fixation has long ... of many ecosystems particularly boreal and temperate forests ... been significant discrepancies between real-world observations and the theories ...
... has been successful in gaining major European Union ... of biological samples, such as DNA, can be ... Europe. The Centre for Integrated Genomic Medical ... Medicine, is playing a key role in developing ...
... N.Y., June 17 bioMETRX, Inc. (OTC,Bulletin Board: ... today announced that the Handgun Club of America ... are showing great interest in,bioMETRX,s smartTOUCH(TM) bioVAULT 2.0 ... with the touch of a finger, and recognition,taking ...
Cached Biology News:Scientists may have solved an ecological riddle 2Manchester clears first hurdle in €170 million biobank building boom 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 3